News FDA Approves RizaFilm® (rizatriptan) Oral Film for the Treatment of Acute Migraine April 17, 2023 Read More » FDA Commissioner and Chief Scientist Announce Decision to Withdraw Approval of Makena April 6, 2023 Read More » Gohibic April 4, 2023 Read More » Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Atovaquone Oral Suspension, USP 750mg/5mL Due to Potential Bacillus Cereus Contamination in the Product March 31, 2023 Read More » FDA Approves First Over-the-Counter Naloxone Nasal Spray March 29, 2023 Read More » Newly Approved Indications March 29, 2023 Read More » Joenja® March 24, 2023 Read More » Rezzayo March 22, 2023 Read More » Ascend Laboratories LLC. Issues Voluntary Nationwide Recall of Dabigatran Etexilate Capsules, USP 75 mg and 150 mg, Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity March 22, 2023 Read More » Page1 Page2 Page3 Page4 Page5 … Page30 Benefit Advisors & Employees - Want to know more? Members: Please call the number on the back of your ID card or e-mail member.services@benecardpbf.com Clients: Contact your Client Relations Manager Full Name(Required) Email(Required) Comment(Required) Company Name(Required) CAPTCHA
FDA Approves RizaFilm® (rizatriptan) Oral Film for the Treatment of Acute Migraine April 17, 2023 Read More »
FDA Commissioner and Chief Scientist Announce Decision to Withdraw Approval of Makena April 6, 2023 Read More »
Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Atovaquone Oral Suspension, USP 750mg/5mL Due to Potential Bacillus Cereus Contamination in the Product March 31, 2023 Read More »
Ascend Laboratories LLC. Issues Voluntary Nationwide Recall of Dabigatran Etexilate Capsules, USP 75 mg and 150 mg, Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity March 22, 2023 Read More »